Yuanda Pharmaceutical (00512): Self-developed, globally innovative radionuclide conjugation drug GPN01530 approved for clinical research in the US

Zhitong Finance App News, Yuanda Pharmaceutical (00512) announced that GPN01530, a globally innovative radionuclide conjugate drug (RDC) independently developed by the Group, recently received official approval from the US Food and Drug Administration (FDA) to carry out phase I/II clinical research to diagnose solid tumors. This marks another solid step in the group's global layout in the field of nuclear drug anti-tumor diagnosis and treatment. As the Group's first self-developed RDC product approved by the FDA to carry out clinical research, the successful approval of GPN01530 clinical research provides an important paradigm for the international development of the Group's nuclear drug product pipeline. It is an important milestone in the global R&D and registration process of the Group's nuclear drug anti-tumor diagnosis and treatment sector, fully demonstrating the Group's comprehensive strength in cutting-edge nuclear drug technology platform construction, international clinical development and registration reporting. Relying on the international registration path of the “China and US Double Newspapers”, the Group will continue to promote global R&D and registration of GPN01530, and use this as a basis to further deepen the sector's global development strategy, actively promote international clinical research and registration of more self-developed innovative nuclear drug products, and continuously enhance the Group's core competitiveness and international influence in the field of anti-tumor diagnosis and treatment of nuclear drugs.